The table below shows RECURSION PHARMACEUTICALS, INC.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
$74.68M
$58.84M
$44.58M
$39.84M
$10.18M
$3.96M
Cost of revenue
$70.95M
$45.24M
$42.59M
$48.27M
$0.00
$0.00
Gross profit
-
-
-
-
-
-
R&D
$475.27M
$314.42M
$241.23M
$155.70M
$135.27M
$63.32M
SG&A
RXRX annual revenue (10-K history)
RECURSION PHARMACEUTICALS, INC. reported annual revenue of $74.68M for fiscal year 2025. That is up 26.9% from $58.84M in fiscal 2024. Over the 7 fiscal years shown, annual revenue grew from $2.32M (FY 2019) to $74.68M. Figures come from the company's audited annual reports as filed with the SEC.
